PENSA study, results of a 12‐month personalized intensive multimodal lifestyle intervention complemented with epigallocatechin gallate (EGCG) to prevent cognitive decline in APOE‐ ɛ4 carriers with Subjective Cognitive Decline: a randomized, double‐blinded clinical trial | Publicación